Back to Search
MAURIE MARKMAN, M.D.
M.D.
Gynecologic Oncology Physician
NPI: 1669564696Individual
Specialties, Licenses & Credentials
Gynecologic Oncology PhysicianPrimary
Obstetrics & Gynecology — Gynecologic Oncology
Code: 207VX0201X
M3806(TX)
Research & Publications (20)
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.
PMID 19447479·Gynecol Oncol·2009
3-trial
Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression.
PMID 19080733·Curr Oncol Rep·2009
8-other
Presentation of chemotherapy options for cervix cancer on cancer-related Internet sites.
PMID 19514823·J Womens Health (Larchmt)·2009
8-other
The myth of measurable disease in ovarian cancer: revisited.
PMID 19160094·Cancer Invest·2009
6-review
Hypersensitivity reactions: an increasingly recognized toxicity of platinum agents.
PMID 19246946·Oncology·2009
8-other
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.
PMID 19395997·Int J Gynecol Cancer·2009
8-other
Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin.
PMID 19436618·Ther Clin Risk Manag·2009
8-other
The promise and perils of 'targeted therapy' of advanced ovarian cancer.
PMID 18536523·Oncology·2008
6-review
Assigning a cause for a particular outcome in oncology: a serious note of caution.
PMID 18506763·Cancer·2008
8-other
Benefits of religious beliefs for cancer patients: a response to Dawkins and Hitchens.
PMID 18765147·Curr Oncol Rep·2008
8-other
Objective data rather than opinion in the interpretation of the legitimate goals of phase 1 oncology trials.
PMID 18181039·Cancer Invest·2008
8-other
Taxanes in the management of gynecologic malignancies.
PMID 18279063·Expert Rev Anticancer Ther·2008
6-review
An ethical argument in support of interactions between developing world countries and pharmaceutical/biotechnology companies involved in oncology drug development.
PMID 18318430·Cancer·2008
8-other
Combination versus sequential chemotherapy administration: is it time for a reevaluation of the issue?
PMID 18377820·Curr Oncol Rep·2008
8-other
"Conflict-of-interest" and participation in IRB deliberations: an alternative perspective.
PMID 18259940·Cancer Invest·2008
6-review
Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
PMID 18760845·Trends Pharmacol Sci·2008
6-review
Prohibition against competing cancer clinical trials: a counter argument.
PMID 18098267·Cancer·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1669564696
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile